JP2014505108A - 認知機能を改善するための方法および組成物 - Google Patents

Info

Publication number

JP2014505108A

JP2014505108A JP2013553575A JP2013553575A JP2014505108A JP 2014505108 A JP2014505108 A JP 2014505108A JP 2013553575 A JP2013553575 A JP 2013553575A JP 2013553575 A JP2013553575 A JP 2013553575A JP 2014505108 A JP2014505108 A JP 2014505108A

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

acceptable salt

hydrate

polymorph

solvate

Prior art date

2011-02-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 200
• 239000000203 mixture Substances 0.000 title claims abstract description 95
• 230000003920 cognitive function Effects 0.000 title claims description 64
• 208000010877 cognitive disease Diseases 0.000 claims abstract description 254
• 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims abstract description 127
• 239000003112 inhibitor Substances 0.000 claims abstract description 113
• 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 104
• 238000011282 treatment Methods 0.000 claims abstract description 89
• 206010012289 Dementia Diseases 0.000 claims abstract description 48
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims abstract description 48
• 229940102566 valproate Drugs 0.000 claims abstract description 48
• 208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 47
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 43
• 208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 41
• 210000003169 central nervous system Anatomy 0.000 claims abstract description 40
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 28
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
• 201000011510 cancer Diseases 0.000 claims abstract description 24
• 150000003839 salts Chemical class 0.000 claims description 213
• 239000012453 solvate Substances 0.000 claims description 145
• HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 59
• 229960004002 levetiracetam Drugs 0.000 claims description 59
• 208000015114 central nervous system disease Diseases 0.000 claims description 36
• MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 30
• 229960002161 brivaracetam Drugs 0.000 claims description 30
• 230000006999 cognitive decline Effects 0.000 claims description 19
• ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims description 18
• 229950000852 seletracetam Drugs 0.000 claims description 18
• 230000007423 decrease Effects 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 238000009472 formulation Methods 0.000 claims description 10
• 239000008280 blood Substances 0.000 claims description 5
• 210000004369 blood Anatomy 0.000 claims description 5
• 230000036571 hydration Effects 0.000 claims description 5
• 238000006703 hydration reaction Methods 0.000 claims description 5
• 239000002904 solvent Substances 0.000 claims description 2
• 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 abstract description 75
• 230000007000 age related cognitive decline Effects 0.000 abstract description 26
• 206010027175 memory impairment Diseases 0.000 abstract description 8
• -1 hydroxy, amino Chemical group 0.000 description 791
• 229910052739 hydrogen Inorganic materials 0.000 description 346
• 239000001257 hydrogen Substances 0.000 description 342
• 125000000217 alkyl group Chemical group 0.000 description 240
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 208
• 229910052736 halogen Inorganic materials 0.000 description 204
• 150000002367 halogens Chemical class 0.000 description 152
• 150000001875 compounds Chemical class 0.000 description 134
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 134
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 131
• 125000003118 aryl group Chemical group 0.000 description 111
• 125000000623 heterocyclic group Chemical group 0.000 description 93
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 78
• UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 73
• 125000001424 substituent group Chemical group 0.000 description 72
• 125000004093 cyano group Chemical group *C#N 0.000 description 64
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 62
• 125000005843 halogen group Chemical group 0.000 description 61
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 54
• 238000012360 testing method Methods 0.000 description 53
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 52
• 125000004432 carbon atom Chemical group C* 0.000 description 50
• 125000003545 alkoxy group Chemical group 0.000 description 49
• 125000002252 acyl group Chemical group 0.000 description 40
• 125000003342 alkenyl group Chemical group 0.000 description 38
• 150000001408 amides Chemical class 0.000 description 38
• 238000010171 animal model Methods 0.000 description 38
• 150000002148 esters Chemical class 0.000 description 36
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 36
• 241000700159 Rattus Species 0.000 description 35
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 35
• 125000000304 alkynyl group Chemical group 0.000 description 33
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 32
• 125000004149 thio group Chemical group *S* 0.000 description 32
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 32
• 125000004414 alkyl thio group Chemical group 0.000 description 31
• 150000001540 azides Chemical class 0.000 description 30
• 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 26
• DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 26
• 125000000753 cycloalkyl group Chemical group 0.000 description 26
• 125000001309 chloro group Chemical group Cl* 0.000 description 25
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 25
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
• 239000003795 chemical substances by application Substances 0.000 description 24
• 230000001149 cognitive effect Effects 0.000 description 22
• 241000282412 Homo Species 0.000 description 20
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• 230000015654 memory Effects 0.000 description 20
• 208000024891 symptom Diseases 0.000 description 20
• 229910052794 bromium Inorganic materials 0.000 description 19
• 239000000460 chlorine Substances 0.000 description 19
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 19
• 125000003396 thiol group Chemical class [H]S* 0.000 description 19
• 210000004556 brain Anatomy 0.000 description 18
• 229910052731 fluorine Inorganic materials 0.000 description 18
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 18
• 229910052760 oxygen Inorganic materials 0.000 description 18
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 17
• 230000004064 dysfunction Effects 0.000 description 17
• 125000002541 furyl group Chemical group 0.000 description 17
• 239000000902 placebo Substances 0.000 description 17
• 229940068196 placebo Drugs 0.000 description 17
• 125000004076 pyridyl group Chemical group 0.000 description 17
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
• 229910052801 chlorine Inorganic materials 0.000 description 16
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 16
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 16
• 230000006399 behavior Effects 0.000 description 15
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 15
• 208000035475 disorder Diseases 0.000 description 15
• 238000011275 oncology therapy Methods 0.000 description 15
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 15
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 14
• 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 14
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 14
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 14
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 13
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 13
• 241001465754 Metazoa Species 0.000 description 13
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 12
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 12
• 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 12
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 12
• 230000032683 aging Effects 0.000 description 12
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• 239000011737 fluorine Substances 0.000 description 12
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 12
• 125000000335 thiazolyl group Chemical group 0.000 description 12
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 11
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 11
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 11
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 11
• 125000003282 alkyl amino group Chemical group 0.000 description 11
• 150000001412 amines Chemical class 0.000 description 11
• 125000001183 hydrocarbyl group Chemical group 0.000 description 11
• 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 11
• 230000013016 learning Effects 0.000 description 11
• 230000014759 maintenance of location Effects 0.000 description 11
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 11
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 11
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 11
• 230000006886 spatial memory Effects 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 229910052717 sulfur Inorganic materials 0.000 description 11
• 125000001544 thienyl group Chemical group 0.000 description 11
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 11
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 10
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 10
• 125000004104 aryloxy group Chemical group 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 10
• 125000002883 imidazolyl group Chemical group 0.000 description 10
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical group C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 10
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 10
• 125000000168 pyrrolyl group Chemical group 0.000 description 10
• 125000003831 tetrazolyl group Chemical group 0.000 description 10
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 9
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 9
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 9
• 230000000971 hippocampal effect Effects 0.000 description 9
• 125000003386 piperidinyl group Chemical group 0.000 description 9
• 229940124530 sulfonamide Drugs 0.000 description 9
• 150000003456 sulfonamides Chemical class 0.000 description 9
• 230000001629 suppression Effects 0.000 description 9
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 9
• 125000001425 triazolyl group Chemical group 0.000 description 9
• 229920002554 vinyl polymer Polymers 0.000 description 9
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
• 238000012347 Morris Water Maze Methods 0.000 description 8
• 125000001246 bromo group Chemical group Br* 0.000 description 8
• 125000002837 carbocyclic group Chemical group 0.000 description 8
• 125000004122 cyclic group Chemical group 0.000 description 8
• 125000001153 fluoro group Chemical group F* 0.000 description 8
• 125000001624 naphthyl group Chemical group 0.000 description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 description 8
• 125000002971 oxazolyl group Chemical group 0.000 description 8
• 125000004193 piperazinyl group Chemical group 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 238000012549 training Methods 0.000 description 8
• 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 7
• MSTWYMAKOBGMBF-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-phenylpyrrolidin-2-one Chemical compound O=C1CC(C=2C=CC=CC=2)CN1CN1C=CN=C1 MSTWYMAKOBGMBF-UHFFFAOYSA-N 0.000 description 7
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 7
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 7
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 7
• HKNUWEVPOFSOKN-UHFFFAOYSA-N 4-(3-azido-2,4-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=C(N=[N+]=[N-])C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 HKNUWEVPOFSOKN-UHFFFAOYSA-N 0.000 description 7
• BJSNHQAWNWHTOI-UHFFFAOYSA-N [N-]=[N+]=N[S+](C#N)C#N Chemical group [N-]=[N+]=N[S+](C#N)C#N BJSNHQAWNWHTOI-UHFFFAOYSA-N 0.000 description 7
• 125000004423 acyloxy group Chemical group 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 125000005110 aryl thio group Chemical group 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 7
• 238000002599 functional magnetic resonance imaging Methods 0.000 description 7
• 210000001320 hippocampus Anatomy 0.000 description 7
• 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 7
• 230000007074 memory dysfunction Effects 0.000 description 7
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 7
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
• 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 7
• 239000001301 oxygen Substances 0.000 description 7
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 125000000714 pyrimidinyl group Chemical group 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 6
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 6
• DHSHMTXXPHLFOX-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C=NC=C1 DHSHMTXXPHLFOX-UHFFFAOYSA-N 0.000 description 6
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 6
• HYZJCKYKOHLVJF-SFIIULIVSA-N 1H-benzimidazole Chemical group C1=CC=C2N[11CH]=NC2=C1 HYZJCKYKOHLVJF-SFIIULIVSA-N 0.000 description 6
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 6
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 6
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 6
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 6
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
• 125000005236 alkanoylamino group Chemical group 0.000 description 6
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 6
• 125000005135 aryl sulfinyl group Chemical group 0.000 description 6
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 6
• 150000001721 carbon Chemical group 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 230000003111 delayed effect Effects 0.000 description 6
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 6
• 235000013305 food Nutrition 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• 150000004677 hydrates Chemical class 0.000 description 6
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 6
• 125000002757 morpholinyl group Chemical group 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 125000003226 pyrazolyl group Chemical group 0.000 description 6
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 5
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 5
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 5
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
• 239000002253 acid Chemical class 0.000 description 5
• 230000003542 behavioural effect Effects 0.000 description 5
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 5
• KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
• 125000005842 heteroatom Chemical group 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 5
• 210000002475 olfactory pathway Anatomy 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 5
• 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 5
• 230000000007 visual effect Effects 0.000 description 5
• 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
• 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 4
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
• KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 4
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
• 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 230000003935 attention Effects 0.000 description 4
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 4
• ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
• 230000019771 cognition Effects 0.000 description 4
• 230000003930 cognitive ability Effects 0.000 description 4
• 125000000392 cycloalkenyl group Chemical group 0.000 description 4
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 229910052805 deuterium Inorganic materials 0.000 description 4
• 125000005879 dioxolanyl group Chemical group 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 210000005153 frontal cortex Anatomy 0.000 description 4
• 238000003384 imaging method Methods 0.000 description 4
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 4
• 125000002632 imidazolidinyl group Chemical group 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 4
• 125000004538 indolizin-3-yl group Chemical group C=1C=C(N2C=CC=CC12)* 0.000 description 4
• 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 4
• 230000008449 language Effects 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• 230000004770 neurodegeneration Effects 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 125000005936 piperidyl group Chemical group 0.000 description 4
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
• 229930195734 saturated hydrocarbon Natural products 0.000 description 4
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
• 125000001113 thiadiazolyl group Chemical group 0.000 description 4
• 125000000464 thioxo group Chemical group S=* 0.000 description 4
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 3
• 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
• 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 3
• MMPUPJTXJGUJCN-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,3,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C=NC=C3)C2)=C1 MMPUPJTXJGUJCN-UHFFFAOYSA-N 0.000 description 3
• NEGHKNJYVRBUIB-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound C1=C(F)C(F)=CC(F)=C1C1CC(=O)N(CN2C=NC=C2)C1 NEGHKNJYVRBUIB-UHFFFAOYSA-N 0.000 description 3
• IXBCXRXSCZKBQM-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 IXBCXRXSCZKBQM-UHFFFAOYSA-N 0.000 description 3
• STNQVCDNZJBYBD-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-5-methyl-3h-indol-2-one Chemical compound O=C1CC2=CC(C)=CC=C2N1CN1C=CN=C1 STNQVCDNZJBYBD-UHFFFAOYSA-N 0.000 description 3
• YOVXRQGGEBYKRD-UHFFFAOYSA-N 1-[(2-methylimidazol-1-yl)methyl]-4-phenylpyrrolidin-2-one Chemical compound CC1=NC=CN1CN1C(=O)CC(C=2C=CC=CC=2)C1 YOVXRQGGEBYKRD-UHFFFAOYSA-N 0.000 description 3
• TZILDGOHWVEHLW-UHFFFAOYSA-N 1-[(2-nitroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound [O-][N+](=O)C1=NC=CN1CN1C(=O)CC(C=2C=C(F)C(F)=C(F)C=2)C1 TZILDGOHWVEHLW-UHFFFAOYSA-N 0.000 description 3
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 3
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 3
• 125000004637 2-oxopiperidinyl group Chemical class O=C1N(CCCC1)* 0.000 description 3
• WMFWFSQIINJUOM-UHFFFAOYSA-N 3-[(5-chloro-2-oxo-3h-indol-1-yl)methyl]imidazole-4-carbonitrile Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CN1C=NC=C1C#N WMFWFSQIINJUOM-UHFFFAOYSA-N 0.000 description 3
• RVNGBMKIPMYIRW-UHFFFAOYSA-N 3-[[2-oxo-4-(2,3,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C(=CN=C3)C#N)C2)=C1 RVNGBMKIPMYIRW-UHFFFAOYSA-N 0.000 description 3
• LWOVRKKVJJZLHR-UHFFFAOYSA-N 3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)C#N)C2)=C1 LWOVRKKVJJZLHR-UHFFFAOYSA-N 0.000 description 3
• GVOMOCYUXNMCEE-UHFFFAOYSA-N 4-(2,2-difluoroethenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound O=C1CC(C=C(F)F)CN1CN1C=NC=C1 GVOMOCYUXNMCEE-UHFFFAOYSA-N 0.000 description 3
• FOGVTCIVYTZIHU-UHFFFAOYSA-N 4-(3-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=CC=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 FOGVTCIVYTZIHU-UHFFFAOYSA-N 0.000 description 3
• VBZNNYAMASHGAS-UHFFFAOYSA-N 5-chloro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CN1C=CN=C1 VBZNNYAMASHGAS-UHFFFAOYSA-N 0.000 description 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000000044 Amnesia Diseases 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• 125000001769 aryl amino group Chemical group 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000003931 cognitive performance Effects 0.000 description 3
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 230000001934 delay Effects 0.000 description 3
• 125000004431 deuterium atom Chemical group 0.000 description 3
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 3
• 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 3
• 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 3
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 3
• 125000001041 indolyl group Chemical group 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000007689 inspection Methods 0.000 description 3
• 125000002346 iodo group Chemical group I* 0.000 description 3
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 3
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 3
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 3
• 125000005956 isoquinolyl group Chemical group 0.000 description 3
• 125000001786 isothiazolyl group Chemical group 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 230000037023 motor activity Effects 0.000 description 3
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 3
• 230000003557 neuropsychological effect Effects 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 3
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 3
• 125000003884 phenylalkyl group Chemical group 0.000 description 3
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
• 230000003518 presynaptic effect Effects 0.000 description 3
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
• 125000003373 pyrazinyl group Chemical group 0.000 description 3
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 3
• 125000002098 pyridazinyl group Chemical group 0.000 description 3
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
• 125000005493 quinolyl group Chemical group 0.000 description 3
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011069 regeneration method Methods 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 238000010187 selection method Methods 0.000 description 3
• 125000003003 spiro group Chemical group 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 230000000946 synaptic effect Effects 0.000 description 3
• 230000003977 synaptic function Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 3
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
• 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 description 2
• 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 2
• FOBQCCYFIYFYCL-UHFFFAOYSA-N 1-(2-azido-1-imidazol-1-ylethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1C(CN=[N+]=[N-])N1C=NC=C1 FOBQCCYFIYFYCL-UHFFFAOYSA-N 0.000 description 2
• WQXXAPQIKCSYOZ-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1CN1C=CN=C1 WQXXAPQIKCSYOZ-UHFFFAOYSA-N 0.000 description 2
• YSOSTGVXSIEDJS-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)-4-(2,3,4-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 YSOSTGVXSIEDJS-UHFFFAOYSA-N 0.000 description 2
• SWMPTLGPAJVHDH-UHFFFAOYSA-N 1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound O=C1CCCN1CN1C=NC=C1 SWMPTLGPAJVHDH-UHFFFAOYSA-N 0.000 description 2
• VKOZRIVWEOKRMT-UHFFFAOYSA-N 1-[(2-aminoimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(N)=NC=C1 VKOZRIVWEOKRMT-UHFFFAOYSA-N 0.000 description 2
• GTCYFTFNSRQATN-UHFFFAOYSA-N 1-[(2-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC=C3)Cl)C2)=C1 GTCYFTFNSRQATN-UHFFFAOYSA-N 0.000 description 2
• DCNPOBXGKYOEQH-UHFFFAOYSA-N 1-[(2-chloroimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(Cl)=NC=C1 DCNPOBXGKYOEQH-UHFFFAOYSA-N 0.000 description 2
• XNAQRBOXVOAHBN-UHFFFAOYSA-N 1-[(2-ethylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CC)=NC=C1 XNAQRBOXVOAHBN-UHFFFAOYSA-N 0.000 description 2
• LDMXDEBMEOWRSK-UHFFFAOYSA-N 1-[(2-methylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=NC=C1 LDMXDEBMEOWRSK-UHFFFAOYSA-N 0.000 description 2
• QGLHAQWFXLLYML-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]-2-propylbenzimidazole-5-carbonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C#N)C=C2N=C1CCC QGLHAQWFXLLYML-UHFFFAOYSA-N 0.000 description 2
• MWSZIXPMBFLEIE-UHFFFAOYSA-N 1-[(5-fluoro-2-propylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1CCC MWSZIXPMBFLEIE-UHFFFAOYSA-N 0.000 description 2
• BNGFLFZUFMSFJR-UHFFFAOYSA-N 1-[[2-oxo-4-(2,3,4-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=C(N=C2)C#N)C1 BNGFLFZUFMSFJR-UHFFFAOYSA-N 0.000 description 2
• VQWUGPBCGAUXGV-UHFFFAOYSA-N 1-[[2-oxo-4-(2,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound C1=C(F)C(F)=CC(F)=C1C1CC(=O)N(CN2C=C(N=C2)C#N)C1 VQWUGPBCGAUXGV-UHFFFAOYSA-N 0.000 description 2
• XOPQGGKKILEZAJ-UHFFFAOYSA-N 1-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=C(N=C3)C#N)C2)=C1 XOPQGGKKILEZAJ-UHFFFAOYSA-N 0.000 description 2
• NARQRGWNGUTSFR-UHFFFAOYSA-N 1-amino-2-cyano-1-nitroguanidine Chemical compound [O-][N+](=O)N(N)C(N)=NC#N NARQRGWNGUTSFR-UHFFFAOYSA-N 0.000 description 2
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
• 125000006039 1-hexenyl group Chemical group 0.000 description 2
• 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 2
• 125000006017 1-propenyl group Chemical group 0.000 description 2
• 238000010176 18-FDG-positron emission tomography Methods 0.000 description 2
• 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
• ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
• 125000006040 2-hexenyl group Chemical group 0.000 description 2
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
• 125000006046 3-methyl-1-pentenyl group Chemical group 0.000 description 2
• XESLNBDOUQCRDD-UHFFFAOYSA-N 4-(3,5-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound FC1=CC(F)=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 XESLNBDOUQCRDD-UHFFFAOYSA-N 0.000 description 2
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
• WGLPSOPOISZEPO-UHFFFAOYSA-N 4-propyl-1-[(2-propylimidazol-1-yl)methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CCC)=NC=C1 WGLPSOPOISZEPO-UHFFFAOYSA-N 0.000 description 2
• DNAWBWYYCPAJSG-UHFFFAOYSA-N 4-propyl-1-[[2-(1H-pyrrol-2-yl)benzimidazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C1=CC=CN1 DNAWBWYYCPAJSG-UHFFFAOYSA-N 0.000 description 2
• WPGIUQJYAKHGHL-UHFFFAOYSA-N 7-[(3-bromophenyl)methyl]-3-methyl-8-pentan-3-ylsulfanylpurine-2,6-dione Chemical compound CCC(CC)SC1=NC=2N(C)C(=O)NC(=O)C=2N1CC1=CC=CC(Br)=C1 WPGIUQJYAKHGHL-UHFFFAOYSA-N 0.000 description 2
• 206010001497 Agitation Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 125000003860 C1-C20 alkoxy group Chemical group 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108700012941 GNRH1 Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 201000002832 Lewy body dementia Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
• 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
• 125000002015 acyclic group Chemical group 0.000 description 2
• 125000006323 alkenyl amino group Chemical group 0.000 description 2
• 125000003302 alkenyloxy group Chemical group 0.000 description 2
• 125000005136 alkenylsulfinyl group Chemical group 0.000 description 2
• 125000005137 alkenylsulfonyl group Chemical group 0.000 description 2
• 125000005108 alkenylthio group Chemical group 0.000 description 2
• 125000005037 alkyl phenyl group Chemical group 0.000 description 2
• 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
• 125000006319 alkynyl amino group Chemical group 0.000 description 2
• 125000004419 alkynylene group Chemical group 0.000 description 2
• 125000005133 alkynyloxy group Chemical group 0.000 description 2
• 125000005134 alkynylsulfinyl group Chemical group 0.000 description 2
• 125000005139 alkynylsulfonyl group Chemical group 0.000 description 2
• 125000005109 alkynylthio group Chemical group 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 125000003725 azepanyl group Chemical group 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 229940092714 benzenesulfonic acid Drugs 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
• 230000003925 brain function Effects 0.000 description 2
• 125000004799 bromophenyl group Chemical group 0.000 description 2
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
• 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000003750 conditioning effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• MVHPKFQBHWGTQH-UHFFFAOYSA-N cyano(nitro)carbamic acid Chemical compound OC(=O)N(C#N)[N+]([O-])=O MVHPKFQBHWGTQH-UHFFFAOYSA-N 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• JCEYKTSZCHPLIB-UHFFFAOYSA-N diazonio(thiocyanato)azanide Chemical compound [N-]=[N+]=NSC#N JCEYKTSZCHPLIB-UHFFFAOYSA-N 0.000 description 2
• 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 2
• 230000002996 emotional effect Effects 0.000 description 2
• 238000013265 extended release Methods 0.000 description 2
• 125000001207 fluorophenyl group Chemical group 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 125000004031 fumaroyl group Chemical group C(\C=C\C(=O)*)(=O)* 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000009760 functional impairment Effects 0.000 description 2
• 125000003838 furazanyl group Chemical group 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 125000004470 heterocyclooxy group Chemical group 0.000 description 2
• 150000002402 hexoses Chemical class 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 230000010365 information processing Effects 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 229940074869 marquis Drugs 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000007087 memory ability Effects 0.000 description 2
• 230000008897 memory decline Effects 0.000 description 2
• 230000006984 memory degeneration Effects 0.000 description 2
• 208000023060 memory loss Diseases 0.000 description 2
• 230000007595 memory recall Effects 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 210000002161 motor neuron Anatomy 0.000 description 2
• IPUFTCVRWHWVKL-UHFFFAOYSA-N n-azidonitramide Chemical compound [O-][N+](=O)NN=[N+]=[N-] IPUFTCVRWHWVKL-UHFFFAOYSA-N 0.000 description 2
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 125000006501 nitrophenyl group Chemical group 0.000 description 2
• 125000000962 organic group Chemical group 0.000 description 2
• 125000003431 oxalo group Chemical group 0.000 description 2
• 125000003355 oxamoyl group Chemical group C(C(=O)N)(=O)* 0.000 description 2
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 150000002972 pentoses Chemical class 0.000 description 2
• 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 2
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 210000002442 prefrontal cortex Anatomy 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
• 102000016914 ras Proteins Human genes 0.000 description 2
• 108010014186 ras Proteins Proteins 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000004576 sand Substances 0.000 description 2
• 230000000698 schizophrenic effect Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 125000000547 substituted alkyl group Chemical group 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000001984 thiazolidinyl group Chemical group 0.000 description 2
• 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 238000003325 tomography Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• DGHFMPOTXCGXRM-HKGPVOKGSA-N (2s)-2-(2-oxopyrrolidin-1-yl)butanamide Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O.CC[C@@H](C(N)=O)N1CCCC1=O DGHFMPOTXCGXRM-HKGPVOKGSA-N 0.000 description 1
• LYHWYWWLWAVRMW-YUMQZZPRSA-N (2s)-2-[(4r)-4-(iodomethyl)-2-oxopyrrolidin-1-yl]-n-methylbutanamide Chemical compound CNC(=O)[C@H](CC)N1C[C@H](CI)CC1=O LYHWYWWLWAVRMW-YUMQZZPRSA-N 0.000 description 1
• HXSYUKBJWISQLD-MQWKRIRWSA-N (2s)-2-[2-oxo-4-(tetrazol-1-ylmethyl)pyrrolidin-1-yl]butanamide Chemical compound C1C(=O)N([C@@H](CC)C(N)=O)CC1CN1N=NN=C1 HXSYUKBJWISQLD-MQWKRIRWSA-N 0.000 description 1
• UMWCSODNRCPYON-HACHORDNSA-N (2s)-2-[4-(2-iodopropyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CC(C)I)CC1=O UMWCSODNRCPYON-HACHORDNSA-N 0.000 description 1
• PAMQVXOBQOEDRC-MQWKRIRWSA-N (2s)-2-[4-(iodomethyl)-2-oxopiperidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CCC(CI)CC1=O PAMQVXOBQOEDRC-MQWKRIRWSA-N 0.000 description 1
• MUAFOMJSWIWBTJ-MLWJPKLSSA-N (2s)-2-[4-(iodomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CI)CC1=O MUAFOMJSWIWBTJ-MLWJPKLSSA-N 0.000 description 1
• AODIMRJCLWXUFM-MQWKRIRWSA-N (2s)-2-[4-(isothiocyanatomethyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CC[C@@H](C(N)=O)N1CC(CN=C=S)CC1=O AODIMRJCLWXUFM-MQWKRIRWSA-N 0.000 description 1
• 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
• 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
• 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
• 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
• 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 1
• 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• NLSXMAXNRDFBKV-UHFFFAOYSA-N 1-(1-imidazol-1-ylcyclopropyl)pyrrolidin-2-one Chemical compound O=C1CCCN1C1(N2C=NC=C2)CC1 NLSXMAXNRDFBKV-UHFFFAOYSA-N 0.000 description 1
• FRWMDIJYYSPZAZ-UHFFFAOYSA-N 1-(1h-benzimidazol-4-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CC=CC2=C1NC=N2 FRWMDIJYYSPZAZ-UHFFFAOYSA-N 0.000 description 1
• YBKBOKXXZSREFD-UHFFFAOYSA-N 1-(benzimidazol-1-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1 YBKBOKXXZSREFD-UHFFFAOYSA-N 0.000 description 1
• UJUVIQXRTXUKEY-UHFFFAOYSA-N 1-(imidazo[1,2-a]pyridin-3-ylmethyl)-4-phenylpyrrolidin-2-one Chemical compound C1N(CC=2N3C=CC=CC3=NC=2)C(=O)CC1C1=CC=CC=C1 UJUVIQXRTXUKEY-UHFFFAOYSA-N 0.000 description 1
• OGWWPJWMSADGCU-UHFFFAOYSA-N 1-(imidazo[1,2-a]pyridin-3-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=CC=C2 OGWWPJWMSADGCU-UHFFFAOYSA-N 0.000 description 1
• DDMQLMXTXBQYAS-UHFFFAOYSA-N 1-(imidazo[1,2-a]pyrimidin-3-ylmethyl)-4-phenylpyrrolidin-2-one Chemical compound C1N(CC=2N3C=CC=NC3=NC=2)C(=O)CC1C1=CC=CC=C1 DDMQLMXTXBQYAS-UHFFFAOYSA-N 0.000 description 1
• LJTRTVWEDDKARB-UHFFFAOYSA-N 1-(imidazo[1,2-a]pyrimidin-3-ylmethyl)-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=CC=N2 LJTRTVWEDDKARB-UHFFFAOYSA-N 0.000 description 1
• LILRFAHFFHHJTB-UHFFFAOYSA-N 1-[(2,4-dichloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC(Cl)=C3)Cl)C2)=C1 LILRFAHFFHHJTB-UHFFFAOYSA-N 0.000 description 1
• DMWXHPXTQSABEU-UHFFFAOYSA-N 1-[(2,5-dimethylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=NC=C1C DMWXHPXTQSABEU-UHFFFAOYSA-N 0.000 description 1
• DXFJCDZVYSJJJW-UHFFFAOYSA-N 1-[(2-aminobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1N DXFJCDZVYSJJJW-UHFFFAOYSA-N 0.000 description 1
• HZIUYKJGHVOBOT-UHFFFAOYSA-N 1-[(2-bromo-4,5-dichloroimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(Cl)=C(Cl)N=C1Br HZIUYKJGHVOBOT-UHFFFAOYSA-N 0.000 description 1
• NPXIRSLQRQEOIW-UHFFFAOYSA-N 1-[(2-chloroimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(Cl)N=C2N1C=CC=C2 NPXIRSLQRQEOIW-UHFFFAOYSA-N 0.000 description 1
• WFNPPGOEDWYTLY-UHFFFAOYSA-N 1-[(2-cyclopropyl-5-fluorobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1C1CC1 WFNPPGOEDWYTLY-UHFFFAOYSA-N 0.000 description 1
• YESZUXWWZNLVAL-UHFFFAOYSA-N 1-[(2-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-4-(2,2-difluoroethenyl)pyrrolidin-2-one Chemical compound O=C1CC(C=C(F)F)CN1CC1=C(C2CC2)N=C2N1C=C(F)C=C2 YESZUXWWZNLVAL-UHFFFAOYSA-N 0.000 description 1
• KMJYGLVZFWVDEX-UHFFFAOYSA-N 1-[(2-methylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C KMJYGLVZFWVDEX-UHFFFAOYSA-N 0.000 description 1
• UEHLNJNATLEAND-UHFFFAOYSA-N 1-[(2-methylsulfanylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1SC UEHLNJNATLEAND-UHFFFAOYSA-N 0.000 description 1
• UZTJMVPOHMVXDB-UHFFFAOYSA-N 1-[(2-methylsulfanylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(SC)=NC=C1 UZTJMVPOHMVXDB-UHFFFAOYSA-N 0.000 description 1
• WSNFJRAAUWGARO-UHFFFAOYSA-N 1-[(2-methylsulfinylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(S(C)=O)=NC=C1 WSNFJRAAUWGARO-UHFFFAOYSA-N 0.000 description 1
• QRILSCCZFKIUCY-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]-2-(1h-pyrazol-5-yl)benzimidazole-5-carbonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C#N)C=C2N=C1C1=NNC=C1 QRILSCCZFKIUCY-UHFFFAOYSA-N 0.000 description 1
• KYAPYLNXHWPLFH-UHFFFAOYSA-N 1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]imidazole-2-carboxamide Chemical compound O=C1CC(CCC)CN1CN1C(C(N)=O)=NC=C1 KYAPYLNXHWPLFH-UHFFFAOYSA-N 0.000 description 1
• UBSFWHNQTAFWBM-UHFFFAOYSA-N 1-[(2-phenylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C=2C=CC=CC=2)=NC=C1 UBSFWHNQTAFWBM-UHFFFAOYSA-N 0.000 description 1
• ADVHAHAQXNXOFM-UHFFFAOYSA-N 1-[(2-propan-2-ylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C(C)C)=NC=C1 ADVHAHAQXNXOFM-UHFFFAOYSA-N 0.000 description 1
• CDXQIJLBOKUEKP-UHFFFAOYSA-N 1-[(2-tert-butylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C(C)(C)C)=NC=C1 CDXQIJLBOKUEKP-UHFFFAOYSA-N 0.000 description 1
• LGPSJLFGKUBRRN-UHFFFAOYSA-N 1-[(3-methylbenzimidazol-5-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CC=C(N=CN2C)C2=C1 LGPSJLFGKUBRRN-UHFFFAOYSA-N 0.000 description 1
• JQNJBZAGGUCOSU-UHFFFAOYSA-N 1-[(4-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C=C(Cl)N=C3)C2)=C1 JQNJBZAGGUCOSU-UHFFFAOYSA-N 0.000 description 1
• LPNDHLTVKWGIKX-UHFFFAOYSA-N 1-[(5-chloroimidazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)Cl)C2)=C1 LPNDHLTVKWGIKX-UHFFFAOYSA-N 0.000 description 1
• LYRJZOWYSWXWAV-UHFFFAOYSA-N 1-[(5-fluoro-2-propan-2-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1C(C)C LYRJZOWYSWXWAV-UHFFFAOYSA-N 0.000 description 1
• FIUGWBYGVGENPO-UHFFFAOYSA-N 1-[(5-methoxybenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(OC)C=C2N=C1 FIUGWBYGVGENPO-UHFFFAOYSA-N 0.000 description 1
• YEEVNDQHPQCKCW-UHFFFAOYSA-N 1-[(5-methyl-2-phenylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C=2C=CC=CC=2)=NC=C1C YEEVNDQHPQCKCW-UHFFFAOYSA-N 0.000 description 1
• LIWLHNXMHAKMRL-UHFFFAOYSA-N 1-[(5-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-phenylpyrrolidin-2-one Chemical compound N12C(C)=CC=CC2=NC=C1CN(C(C1)=O)CC1C1=CC=CC=C1 LIWLHNXMHAKMRL-UHFFFAOYSA-N 0.000 description 1
• RYELIZJHVRUBPL-UHFFFAOYSA-N 1-[(5-methylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C)=CN=C1 RYELIZJHVRUBPL-UHFFFAOYSA-N 0.000 description 1
• XZAPIBFOEWKGEW-UHFFFAOYSA-N 1-[(5-phenylimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(C=2C=CC=CC=2)=CN=C1 XZAPIBFOEWKGEW-UHFFFAOYSA-N 0.000 description 1
• RWGACOXCJJDBPT-UHFFFAOYSA-N 1-[(6,8-dibromoimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(Br)C=C2Br RWGACOXCJJDBPT-UHFFFAOYSA-N 0.000 description 1
• UOUMTLHYOKDMHW-UHFFFAOYSA-N 1-[(6,8-dichloroimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(Cl)C=C2Cl UOUMTLHYOKDMHW-UHFFFAOYSA-N 0.000 description 1
• DXSIQCCKLIYGMD-UHFFFAOYSA-N 1-[(6-bromoimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(Br)C=C2 DXSIQCCKLIYGMD-UHFFFAOYSA-N 0.000 description 1
• VZXXOCBQPGAMSM-UHFFFAOYSA-N 1-[(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-4-(2,2-difluoroethenyl)pyrrolidin-2-one Chemical compound O=C1CC(C=C(F)F)CN1CC1=C(C2CC2)N=C2N1C=C(Cl)C=C2 VZXXOCBQPGAMSM-UHFFFAOYSA-N 0.000 description 1
• UQYJOXGLENVZOQ-UHFFFAOYSA-N 1-[(6-chloro-2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C2CC2)N=C2N1N=C(Cl)C=C2 UQYJOXGLENVZOQ-UHFFFAOYSA-N 0.000 description 1
• POYAFCUMHBKUJT-UHFFFAOYSA-N 1-[(6-chlorobenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(Cl)=CC=C2N=C1 POYAFCUMHBKUJT-UHFFFAOYSA-N 0.000 description 1
• LIMALWRGMYNGLD-UHFFFAOYSA-N 1-[(6-chloroimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(Cl)C=C2 LIMALWRGMYNGLD-UHFFFAOYSA-N 0.000 description 1
• MKOHPDFGQRFRJS-UHFFFAOYSA-N 1-[(6-chloroimidazo[1,2-a]pyrimidin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(Cl)C=N2 MKOHPDFGQRFRJS-UHFFFAOYSA-N 0.000 description 1
• OIROQURGSQOQFW-UHFFFAOYSA-N 1-[(6-chloroimidazo[1,2-b]pyridazin-3-yl)methyl]-4-phenylpyrrolidin-2-one Chemical compound N12N=C(Cl)C=CC2=NC=C1CN(C(C1)=O)CC1C1=CC=CC=C1 OIROQURGSQOQFW-UHFFFAOYSA-N 0.000 description 1
• XLJPZYBRVGMZDK-UHFFFAOYSA-N 1-[(6-chloroimidazo[1,2-b]pyridazin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1N=C(Cl)C=C2 XLJPZYBRVGMZDK-UHFFFAOYSA-N 0.000 description 1
• DXHYJPDEWCUVKU-UHFFFAOYSA-N 1-[(6-iodoimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(I)C=C2 DXHYJPDEWCUVKU-UHFFFAOYSA-N 0.000 description 1
• ODGJZBDHLRKMJH-UHFFFAOYSA-N 1-[(6-methoxy-2-pentan-3-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C(CC)CC ODGJZBDHLRKMJH-UHFFFAOYSA-N 0.000 description 1
• XXAIPQNCTCVZLJ-UHFFFAOYSA-N 1-[(6-methoxy-2-propan-2-ylbenzimidazol-1-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC(OC)=CC=C2N=C1C(C)C XXAIPQNCTCVZLJ-UHFFFAOYSA-N 0.000 description 1
• WEOQNXMQRDDUAX-UHFFFAOYSA-N 1-[(6-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(C)C=C2 WEOQNXMQRDDUAX-UHFFFAOYSA-N 0.000 description 1
• ZKJMGZQMOMEPDJ-UHFFFAOYSA-N 1-[(6-phenylimidazo[1,2-b][1,2,4]triazin-7-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC=CC=2)N=C2N1N=CC=N2 ZKJMGZQMOMEPDJ-UHFFFAOYSA-N 0.000 description 1
• ITAOTQZOWNSWCB-UHFFFAOYSA-N 1-[(7-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=CC(C)=C2 ITAOTQZOWNSWCB-UHFFFAOYSA-N 0.000 description 1
• GXSAOFWXQIMXEE-UHFFFAOYSA-N 1-[(8-methylimidazo[1,2-a]pyridin-3-yl)methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=CC=C2C GXSAOFWXQIMXEE-UHFFFAOYSA-N 0.000 description 1
• BWUYHRBEWKNROO-UHFFFAOYSA-N 1-[1-(2-methylsulfonylimidazol-1-yl)butan-2-yl]pyrrolidin-2-one Chemical compound C1CCC(=O)N1C(CC)CN1C=CN=C1S(C)(=O)=O BWUYHRBEWKNROO-UHFFFAOYSA-N 0.000 description 1
• PLOISAVDJJVIDJ-UHFFFAOYSA-N 1-[2-(5-chloro-2-oxo-3h-indol-1-yl)acetyl]-2,3,4a,5,6,7,8,8a-octahydroquinolin-4-one Chemical compound C1CC(=O)C2CCCCC2N1C(=O)CN1C2=CC=C(Cl)C=C2CC1=O PLOISAVDJJVIDJ-UHFFFAOYSA-N 0.000 description 1
• QINPXWIQALJJMO-UHFFFAOYSA-N 1-[[2-(1H-imidazol-2-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=NC=CN1 QINPXWIQALJJMO-UHFFFAOYSA-N 0.000 description 1
• BNKDDYUJRZNHNO-UHFFFAOYSA-N 1-[[2-(2-methylsulfanylethyl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1CCSC BNKDDYUJRZNHNO-UHFFFAOYSA-N 0.000 description 1
• RKFOXDHYWAXPJK-UHFFFAOYSA-N 1-[[2-(4-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC(Cl)=CC=2)N=C2N1C=C(C)C=C2 RKFOXDHYWAXPJK-UHFFFAOYSA-N 0.000 description 1
• WVCWRRKDJLZMOX-UHFFFAOYSA-N 1-[[2-(4-chlorophenyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC(Cl)=CC=2)N=C2N1C=CC=N2 WVCWRRKDJLZMOX-UHFFFAOYSA-N 0.000 description 1
• LWNMPCACKLXIGW-UHFFFAOYSA-N 1-[[2-(chloromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1CCl LWNMPCACKLXIGW-UHFFFAOYSA-N 0.000 description 1
• YTSOXQXOEYSMDY-UHFFFAOYSA-N 1-[[2-(furan-3-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=COC=C1 YTSOXQXOEYSMDY-UHFFFAOYSA-N 0.000 description 1
• HQVGICWOGFCPOQ-UHFFFAOYSA-N 1-[[2-ethyl-5-(trifluoromethyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1CC HQVGICWOGFCPOQ-UHFFFAOYSA-N 0.000 description 1
• PTFZZCVHKGBHJB-UHFFFAOYSA-N 1-[[2-oxo-4-(2,3,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-4-carbonitrile Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CN3C=C(N=C3)C#N)C2)=C1 PTFZZCVHKGBHJB-UHFFFAOYSA-N 0.000 description 1
• DBFRVXYBWNTDHI-UHFFFAOYSA-N 1-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazole-2-carbonitrile Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=NC=C3)C#N)C2)=C1 DBFRVXYBWNTDHI-UHFFFAOYSA-N 0.000 description 1
• SSAQPVYFAJYUNL-UHFFFAOYSA-N 1-[[4-(hydroxymethyl)imidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C=C(CO)N=C1 SSAQPVYFAJYUNL-UHFFFAOYSA-N 0.000 description 1
• XRVKADPALQVQMA-UHFFFAOYSA-N 1-[[5-(hydroxymethyl)imidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C(CO)=CN=C1 XRVKADPALQVQMA-UHFFFAOYSA-N 0.000 description 1
• NFADAGRMESZNPI-UHFFFAOYSA-N 1-[[5-fluoro-2-(2,4,4-trimethylpentyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1CC(C)CC(C)(C)C NFADAGRMESZNPI-UHFFFAOYSA-N 0.000 description 1
• OLGMRLYGERNLFL-UHFFFAOYSA-N 1-[[5-fluoro-2-(2-methylpropyl)benzimidazol-1-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(F)C=C2N=C1CC(C)C OLGMRLYGERNLFL-UHFFFAOYSA-N 0.000 description 1
• MSWBDXWEVVVAMM-UHFFFAOYSA-N 1-[[6-chloro-2-(4-chlorophenyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC(Cl)=CC=2)N=C2N1N=C(Cl)C=C2 MSWBDXWEVVVAMM-UHFFFAOYSA-N 0.000 description 1
• CJHALJYIXICDEL-UHFFFAOYSA-N 1-[[6-chloro-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC(C)=CC=2)N=C2N1C=C(Cl)C=C2 CJHALJYIXICDEL-UHFFFAOYSA-N 0.000 description 1
• SGRZAFJSWRLYGP-UHFFFAOYSA-N 1-[[6-chloro-2-(4-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C=2C=CC(C)=CC=2)N=C2N1N=C(Cl)C=C2 SGRZAFJSWRLYGP-UHFFFAOYSA-N 0.000 description 1
• HQDJFFSANVRKPQ-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C(F)(F)F)N=C2N1C=C(Cl)C=N2 HQDJFFSANVRKPQ-UHFFFAOYSA-N 0.000 description 1
• NCJWJBZENQJHAD-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-(2,2-difluoroethenyl)pyrrolidin-2-one Chemical compound O=C1CC(C=C(F)F)CN1CC1=C(C(F)(F)F)N=C2N1N=C(Cl)C=C2 NCJWJBZENQJHAD-UHFFFAOYSA-N 0.000 description 1
• QKSMBFUZSFGEQV-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-(2,3,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=CC(F)=C(F)C(C2CC(=O)N(CC=3N4N=C(Cl)C=CC4=NC=3C(F)(F)F)C2)=C1 QKSMBFUZSFGEQV-UHFFFAOYSA-N 0.000 description 1
• DVMJEEOWFZDBFI-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-phenylpyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2C=CC(Cl)=NN2C=1CN(C(C1)=O)CC1C1=CC=CC=C1 DVMJEEOWFZDBFI-UHFFFAOYSA-N 0.000 description 1
• DAHWBFGUGGFLBE-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C(F)(F)F)N=C2N1N=C(Cl)C=C2 DAHWBFGUGGFLBE-UHFFFAOYSA-N 0.000 description 1
• FDHKNUVUJULGDI-UHFFFAOYSA-N 1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2C=CC(Cl)=NN2C=1CN1CCCC1=O FDHKNUVUJULGDI-UHFFFAOYSA-N 0.000 description 1
• BRCWMKVMOHGONF-UHFFFAOYSA-N 1-[[6-methoxy-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C(F)(F)F)N=C2N1N=C(OC)C=C2 BRCWMKVMOHGONF-UHFFFAOYSA-N 0.000 description 1
• MXIXCGRKPXFSJH-UHFFFAOYSA-N 1-[[6-propan-2-yloxy-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=C(C(F)(F)F)N=C2N1N=C(OC(C)C)C=C2 MXIXCGRKPXFSJH-UHFFFAOYSA-N 0.000 description 1
• BHFGJUFJVNJPTD-UHFFFAOYSA-N 1-[[8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-4-propylpyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CC1=CN=C2N1C=C(C(F)(F)F)C=C2Cl BHFGJUFJVNJPTD-UHFFFAOYSA-N 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• QXOVTMVRAFZVHN-UHFFFAOYSA-N 2-(2-oxo-4-propylpyrrolidin-1-yl)pent-4-enamide Chemical compound CCCC1CN(C(CC=C)C(N)=O)C(=O)C1 QXOVTMVRAFZVHN-UHFFFAOYSA-N 0.000 description 1
• NLVDSLZEVKVXBN-UHFFFAOYSA-N 2-(4-ethynyl-2-oxopyrrolidin-1-yl)butanamide Chemical compound CCC(C(N)=O)N1CC(C#C)CC1=O NLVDSLZEVKVXBN-UHFFFAOYSA-N 0.000 description 1
• HBLUZXMXGLDADN-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n'-(4,5-dihydro-1h-imidazol-2-yl)acetohydrazide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NNC1=NCCN1 HBLUZXMXGLDADN-UHFFFAOYSA-N 0.000 description 1
• SNTWPDZWBNJRRV-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-cycloheptylacetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NC1CCCCCC1 SNTWPDZWBNJRRV-UHFFFAOYSA-N 0.000 description 1
• HWOGZQLVQPPPLW-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-methoxy-n-methylacetamide Chemical compound ClC1=CC=C2N(CC(=O)N(C)OC)C(=O)CC2=C1 HWOGZQLVQPPPLW-UHFFFAOYSA-N 0.000 description 1
• YCOAHBHANFIXAL-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)-n-pyridin-3-ylacetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NC1=CC=CN=C1 YCOAHBHANFIXAL-UHFFFAOYSA-N 0.000 description 1
• IPCGCGTVOJSBDM-UHFFFAOYSA-N 2-(5-chloro-2-oxo-3h-indol-1-yl)propanamide Chemical compound ClC1=CC=C2N(C(C)C(N)=O)C(=O)CC2=C1 IPCGCGTVOJSBDM-UHFFFAOYSA-N 0.000 description 1
• PCYGBQKZTWTFKK-UHFFFAOYSA-N 2-(5-methyl-2-oxo-3h-indol-1-yl)acetamide Chemical compound CC1=CC=C2N(CC(N)=O)C(=O)CC2=C1 PCYGBQKZTWTFKK-UHFFFAOYSA-N 0.000 description 1
• SIBPXKGLOYCAHH-UHFFFAOYSA-N 2-(5-nitro-2-oxo-3h-indol-1-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=C2N(CC(=O)N)C(=O)CC2=C1 SIBPXKGLOYCAHH-UHFFFAOYSA-N 0.000 description 1
• GWNMNEYLEQQDAE-UHFFFAOYSA-N 2-(7-butyl-3-methyl-2,6-dioxopurin-8-yl)sulfanylbutanamide Chemical compound CN1C(=O)NC(=O)C2=C1N=C(SC(CC)C(N)=O)N2CCCC GWNMNEYLEQQDAE-UHFFFAOYSA-N 0.000 description 1
• RNGWRLQTZHXISD-UHFFFAOYSA-N 2-[1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]benzimidazol-2-yl]acetonitrile Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1CC#N RNGWRLQTZHXISD-UHFFFAOYSA-N 0.000 description 1
• ZPKHWWVHQIJEIN-UHFFFAOYSA-N 2-[4-(2,2-dibromoethenyl)-2-oxopyrrolidin-1-yl]butanamide Chemical compound CCC(C(N)=O)N1CC(C=C(Br)Br)CC1=O ZPKHWWVHQIJEIN-UHFFFAOYSA-N 0.000 description 1
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
• YQXCVVFSHVDWOZ-UHFFFAOYSA-N 2-butyl-1-[(2-oxo-4-propylpyrrolidin-1-yl)methyl]benzimidazole-5-carbonitrile Chemical compound CCCCC1=NC2=CC(C#N)=CC=C2N1CN1CC(CCC)CC1=O YQXCVVFSHVDWOZ-UHFFFAOYSA-N 0.000 description 1
• OCVXSFKKWXMYPF-UHFFFAOYSA-N 2-chloroimidazole Chemical compound ClC1=NC=CN1 OCVXSFKKWXMYPF-UHFFFAOYSA-N 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
• JSLASWSJHUAUMT-UHFFFAOYSA-N 2H-tetrazol-5-yl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OC1=NN=NN1 JSLASWSJHUAUMT-UHFFFAOYSA-N 0.000 description 1
• LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
• ZQOUNEMBXOVYEZ-UHFFFAOYSA-N 3-[(2-oxo-3h-indol-1-yl)methyl]imidazole-4-carbonitrile Chemical compound O=C1CC2=CC=CC=C2N1CN1C=NC=C1C#N ZQOUNEMBXOVYEZ-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• AHRLLKUWLXQABV-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=C(F)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 AHRLLKUWLXQABV-UHFFFAOYSA-N 0.000 description 1
• MPFYXCKDMXTVBZ-UHFFFAOYSA-N 4-(3-chloro-4-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=C(Cl)C(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 MPFYXCKDMXTVBZ-UHFFFAOYSA-N 0.000 description 1
• JUMOXYOJRXHGQN-UHFFFAOYSA-N 4-(3-chlorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound ClC1=CC=CC(C2CC(=O)N(CN3C=NC=C3)C2)=C1 JUMOXYOJRXHGQN-UHFFFAOYSA-N 0.000 description 1
• AFFUFXBLRDLCCR-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=CC(Cl)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 AFFUFXBLRDLCCR-UHFFFAOYSA-N 0.000 description 1
• XVCNDKMWEKVTHG-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-(imidazol-1-ylmethyl)pyrrolidin-2-one Chemical compound C1=CC(F)=CC=C1C1CC(=O)N(CN2C=NC=C2)C1 XVCNDKMWEKVTHG-UHFFFAOYSA-N 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
• HEIFVXKWEVAJPS-UHFFFAOYSA-N 4-chloro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC=2C(Cl)=CC=CC=2N1CN1C=CN=C1 HEIFVXKWEVAJPS-UHFFFAOYSA-N 0.000 description 1
• 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
• IADRSPWONYSJQZ-UHFFFAOYSA-N 4-fluoro-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC=2C(F)=CC=CC=2N1CN1C=CN=C1 IADRSPWONYSJQZ-UHFFFAOYSA-N 0.000 description 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
• RVSXEKKMIIKYJT-UHFFFAOYSA-N 4-propyl-1-[[2-(1H-pyrrol-2-yl)-5-(trifluoromethyl)benzimidazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=C(C(F)(F)F)C=C2N=C1C1=CC=CN1 RVSXEKKMIIKYJT-UHFFFAOYSA-N 0.000 description 1
• KQQGUFXIJMBNAT-UHFFFAOYSA-N 4-propyl-1-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]pyrrolidin-2-one Chemical compound O=C1CC(CCC)CN1CN1C2=CC=CC=C2N=C1C(F)(F)F KQQGUFXIJMBNAT-UHFFFAOYSA-N 0.000 description 1
• YTFGLCMJIBHPEL-UHFFFAOYSA-N 5-bromo-1-(imidazol-1-ylmethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(Br)=CC=C2N1CN1C=CN=C1 YTFGLCMJIBHPEL-UHFFFAOYSA-N 0.000 description 1
• YAJHNRDSDMPURQ-UHFFFAOYSA-N 5-chloro-1-(2-oxo-2-thiomorpholin-4-ylethyl)-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N1CCSCC1 YAJHNRDSDMPURQ-UHFFFAOYSA-N 0.000 description 1
• HNYNQTVEVFCBPP-UHFFFAOYSA-N 5-chloro-1-[2-(2,5-dihydropyrrol-1-yl)-2-oxoethyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N1CC=CC1 HNYNQTVEVFCBPP-UHFFFAOYSA-N 0.000 description 1
• GCXZTFDKFBLXBZ-UHFFFAOYSA-N 5-chloro-1-[2-[4-(3-methylphenyl)piperazin-1-yl]-2-oxoethyl]-3h-indol-2-one Chemical compound CC1=CC=CC(N2CCN(CC2)C(=O)CN2C3=CC=C(Cl)C=C3CC2=O)=C1 GCXZTFDKFBLXBZ-UHFFFAOYSA-N 0.000 description 1
• UZBBHOQMFOGAAV-UHFFFAOYSA-N 5-chloro-1-[2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl]-3h-indol-2-one Chemical compound C1=CC(O)=CC=C1N1CCN(C(=O)CN2C3=CC=C(Cl)C=C3CC2=O)CC1 UZBBHOQMFOGAAV-UHFFFAOYSA-N 0.000 description 1
• KOBSMJYQAHTFOX-UHFFFAOYSA-N 5-chloro-1-[[6-chloro-2-(trifluoromethyl)imidazo[1,2-b]pyridazin-3-yl]methyl]-3h-indol-2-one Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC1=C(C(F)(F)F)N=C2N1N=C(Cl)C=C2 KOBSMJYQAHTFOX-UHFFFAOYSA-N 0.000 description 1
• CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
• XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
• WGDNZPCRCUVXSE-UHFFFAOYSA-N 7-[(3-bromophenyl)methyl]-8-(3-chloro-2-hydroxypropyl)sulfanyl-3-methylpurine-2,6-dione Chemical compound C1=2C(=O)NC(=O)N(C)C=2N=C(SCC(O)CCl)N1CC1=CC=CC(Br)=C1 WGDNZPCRCUVXSE-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• IMEQBMHHNKBAIG-UHFFFAOYSA-N C(C(C)C)N1C(=NC=2N(C(NC(C12)=O)=O)C)SC(C(=O)O)CC Chemical compound C(C(C)C)N1C(=NC=2N(C(NC(C12)=O)=O)C)SC(C(=O)O)CC IMEQBMHHNKBAIG-UHFFFAOYSA-N 0.000 description 1
• 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
• HQPDKJBHTZYFIA-UHFFFAOYSA-N CSC=1N(C=CN1)CN1C(CC(C1)CCC)=O.ClC=1C=C(C=CC1)C1CC(N(C1)CN1C=NC=C1)=O Chemical compound CSC=1N(C=CN1)CN1C(CC(C1)CCC)=O.ClC=1C=C(C=CC1)C1CC(N(C1)CN1C=NC=C1)=O HQPDKJBHTZYFIA-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 206010012205 Delayed puberty Diseases 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• ARAVBCGAELSWGG-UHFFFAOYSA-N FC1=CC=C(C=C1)C1C(N(CC1)CN1C=NC=C1)=O Chemical compound FC1=CC=C(C=C1)C1C(N(CC1)CN1C=NC=C1)=O ARAVBCGAELSWGG-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016754 Flashback Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 101150014889 Gad1 gene Proteins 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 101000584515 Homo sapiens Synaptic vesicle glycoprotein 2B Proteins 0.000 description 1
• 101000584382 Homo sapiens Synaptic vesicle glycoprotein 2C Proteins 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• DWCDRZBUQOQJRV-UHFFFAOYSA-N N#CNC(OO[N+]([O-])=O)=O Chemical compound N#CNC(OO[N+]([O-])=O)=O DWCDRZBUQOQJRV-UHFFFAOYSA-N 0.000 description 1
• POQCOTLKPXNIBT-UHFFFAOYSA-N N-[2-oxo-4-(2,2,2-trifluoroethyl)piperidin-1-yl]butanamide Chemical compound CCCC(=O)NN1CCC(CC(F)(F)F)CC1=O POQCOTLKPXNIBT-UHFFFAOYSA-N 0.000 description 1
• JINHVUKLTLTGOL-UHFFFAOYSA-N N-[5-(5-methylthiophen-2-yl)-2-oxopiperidin-1-yl]butanamide Chemical compound CCCC(=O)NN1CC(CCC1=O)c1ccc(C)s1 JINHVUKLTLTGOL-UHFFFAOYSA-N 0.000 description 1
• RFMGPEMAXTWVEF-UHFFFAOYSA-N NC=1C=C(CN2C(=NC=3N(C(NC(C23)=O)=O)C)SC(C(=O)O)CC)C=CC1 Chemical compound NC=1C=C(CN2C(=NC=3N(C(NC(C23)=O)=O)C)SC(C(=O)O)CC)C=CC1 RFMGPEMAXTWVEF-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• VTVQZSYWQZPECQ-UHFFFAOYSA-O N[S+](C#N)N=[N+]=[N-] Chemical compound N[S+](C#N)N=[N+]=[N-] VTVQZSYWQZPECQ-UHFFFAOYSA-O 0.000 description 1
• 206010056677 Nerve degeneration Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• YQZBRNASSRIGAO-UHFFFAOYSA-N O=C1N(CC(C1)CCC)CN1C(=NC=C1)C(=O)O.OCC=1N(C=CN1)CN1C(CC(C1)CCC)=O Chemical compound O=C1N(CC(C1)CCC)CN1C(=NC=C1)C(=O)O.OCC=1N(C=CN1)CN1C(CC(C1)CCC)=O YQZBRNASSRIGAO-UHFFFAOYSA-N 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 102000001675 Parvalbumin Human genes 0.000 description 1
• 108060005874 Parvalbumin Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 208000013200 Stress disease Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102100030700 Synaptic vesicle glycoprotein 2B Human genes 0.000 description 1
• 102100030637 Synaptic vesicle glycoprotein 2C Human genes 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• HPPOFMGKIIXPKZ-UHFFFAOYSA-N [N+](=O)([O-])OS(=C=NN=[N+]=[N-])C#N Chemical compound [N+](=O)([O-])OS(=C=NN=[N+]=[N-])C#N HPPOFMGKIIXPKZ-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 238000007792 addition Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 102000003802 alpha-Synuclein Human genes 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960004909 aminosalicylic acid Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
• 230000037007 arousal Effects 0.000 description 1
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
• 238000011952 auditory verbal learning test Methods 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000006736 behavioral deficit Effects 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 125000004803 chlorobenzyl group Chemical group 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000005515 coenzyme Substances 0.000 description 1
• 230000006998 cognitive state Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• RFMQOHXWHFHOJF-UHFFFAOYSA-N cyano thiocyanate Chemical compound N#CSC#N RFMQOHXWHFHOJF-UHFFFAOYSA-N 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 210000001947 dentate gyrus Anatomy 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000012954 diazonium Substances 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
• 235000019621 digestibility Nutrition 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003890 endocrine cell Anatomy 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229960004275 glycolic acid Drugs 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 210000004326 gyrus cinguli Anatomy 0.000 description 1
• 230000026781 habituation Effects 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000000232 haloalkynyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 238000012880 independent component analysis Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 210000001153 interneuron Anatomy 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• ZBYZQILPNKOESD-UHFFFAOYSA-N isothiocyanato cyanate Chemical compound S=C=NOC#N ZBYZQILPNKOESD-UHFFFAOYSA-N 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 238000011670 long-evans rat Methods 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010387 memory retrieval Effects 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
• 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• PTHRLIGLRQCNLN-UHFFFAOYSA-N n'-[2-(5-chloro-2-oxo-3h-indol-1-yl)acetyl]pyridine-4-carbohydrazide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)NNC(=O)C1=CC=NC=C1 PTHRLIGLRQCNLN-UHFFFAOYSA-N 0.000 description 1
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
• IXBXPYHKCYTHGU-UHFFFAOYSA-N n-[[3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazol-4-yl]methyl]acetamide Chemical compound CC(=O)NCC1=CN=CN1CN1C(=O)CC(C=2C=C(F)C(F)=C(F)C=2)C1 IXBXPYHKCYTHGU-UHFFFAOYSA-N 0.000 description 1
• YDGYWBNOIIXKPO-UHFFFAOYSA-N n-[[3-[[2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl]imidazol-4-yl]methyl]benzamide Chemical compound FC1=C(F)C(F)=CC(C2CC(=O)N(CN3C(=CN=C3)CNC(=O)C=3C=CC=CC=3)C2)=C1 YDGYWBNOIIXKPO-UHFFFAOYSA-N 0.000 description 1
• PIEJCUCNBNNZST-UHFFFAOYSA-N n-benzyl-2-(5-chloro-2-oxo-3h-indol-1-yl)-n-methylacetamide Chemical compound O=C1CC2=CC(Cl)=CC=C2N1CC(=O)N(C)CC1=CC=CC=C1 PIEJCUCNBNNZST-UHFFFAOYSA-N 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 238000010855 neuropsychological testing Methods 0.000 description 1
• 230000003957 neurotransmitter release Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000001936 parietal effect Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000006977 prepulse inhibition Effects 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 230000010255 response to auditory stimulus Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000006403 short-term memory Effects 0.000 description 1
• 238000002603 single-photon emission computed tomography Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 230000003997 social interaction Effects 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000009154 spontaneous behavior Effects 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 210000002504 synaptic vesicle Anatomy 0.000 description 1
• 102000003137 synaptotagmin Human genes 0.000 description 1
• 108060008004 synaptotagmin Proteins 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 102000013498 tau Proteins Human genes 0.000 description 1
• 108010026424 tau Proteins Proteins 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
• 125000005031 thiocyano group Chemical group S(C#N)* 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000004360 trifluorophenyl group Chemical group 0.000 description 1
• CPPYURNBZOIOQE-UHFFFAOYSA-N trimethyl 5-methylpyrazole-1,3,4-tricarboxylate Chemical compound CC1=C(C(=NN1C(=O)OC)C(=O)OC)C(=O)OC CPPYURNBZOIOQE-UHFFFAOYSA-N 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1
• 239000002676 xenobiotic agent Substances 0.000 description 1